Ameritas Investment Partners’s Aclaris Therapeutics ACRS Stock Holding History

Ameritas Investment Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.9K	Buy	10,756 +1,489	+16%	+$6.64K	﹤0.01%	2185
2026 Q1	$34.8K	Hold	9,267	–	–	﹤0.01%	2306
2025 Q4	$27.9K	Hold	9,267	–	–	﹤0.01%	2478
2025 Q3	$17.6K	Hold	9,267	–	–	﹤0.01%	2719
2025 Q2	$13.2K	Buy	+9,267	New	+$12.5K	﹤0.01%	2858
2024 Q2	–	Sell	-6,900	Closed	-$8.56K	–	3123
2024 Q1	$8.56K	Hold	6,900	–	–	﹤0.01%	2854
2023 Q4	$7.25K	Hold	6,900	–	–	﹤0.01%	2919
2023 Q3	$47.3K	Buy	6,900 +1,731	+33%	+$14.8K	﹤0.01%	2142
2023 Q2	$53.6K	Hold	5,169	–	–	﹤0.01%	2006
2023 Q1	$41.8K	Hold	5,169	–	–	﹤0.01%	2083
2022 Q4	$85.8K	Buy	5,169 +630	+14%	+$10.1K	﹤0.01%	1709
2022 Q3	$71K	Hold	4,539	–	–	﹤0.01%	1727
2022 Q2	$63K	Buy	4,539 +560	+14%	+$7.85K	﹤0.01%	1834
2022 Q1	$69K	Hold	3,979	–	–	﹤0.01%	1866
2021 Q4	$58K	Hold	3,979	–	–	﹤0.01%	2035
2021 Q3	$72K	Buy	3,979 +575	+17%	+$9.22K	﹤0.01%	1901
2021 Q2	$60K	Buy	+3,404	New	+$77.3K	﹤0.01%	2065
2020 Q2	–	Sell	-2,238	Closed	-$2K	–	3060
2020 Q1	$2K	Hold	2,238	–	–	﹤0.01%	2949
2019 Q4	$4K	Hold	2,238	–	–	﹤0.01%	2914
2019 Q3	$2K	Hold	2,238	–	–	﹤0.01%	3009
2019 Q2	$5K	Hold	2,238	–	–	﹤0.01%	2936
2019 Q1	$13K	Hold	2,238	–	–	﹤0.01%	2583
2018 Q4	$17K	Hold	2,238	–	–	﹤0.01%	2422
2018 Q3	$32K	Hold	2,238	–	–	﹤0.01%	2241
2018 Q2	$45K	Buy	2,238 +469	+27%	+$8.66K	﹤0.01%	2046
2018 Q1	$31K	Hold	1,769	–	–	﹤0.01%	2183
2017 Q4	$44K	Hold	1,769	–	–	﹤0.01%	1990
2017 Q3	$45K	Hold	1,769	–	–	﹤0.01%	1955
2017 Q2	$48K	Buy	1,769 +1,067	+152%	+$29K	﹤0.01%	1928
2017 Q1	$21K	Buy	+702	New	+$20.2K	﹤0.01%	2367

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Ameritas Investment Partners's ACRS Position: Q2 2026 in Review

Ameritas Investment Partners increased its Aclaris Therapeutics (ACRS) stake by 16% in Q2 2026, buying an estimated $6.64K and bringing the position to 10,756 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Ameritas Investment Partners first reported a position in ACRS in Q1 2017 and has held it in 30 quarters since. The position peaked at $85.8K in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Ameritas Investment Partners held 10,756 shares of Aclaris Therapeutics worth $56.9K as of Q2 2026.
Ameritas Investment Partners bought 1,489 Aclaris Therapeutics shares in Q2 2026, an estimated $6.64K.
Aclaris Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2185 holding.
Ameritas Investment Partners first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 30 quarters since.
Ameritas Investment Partners's Aclaris Therapeutics position peaked at $85.8K in Q4 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.